| Systems chronotherapeutics A Ballesta, PF Innominato, R Dallmann, DA Rand, FA Lévi Pharmacological reviews 69 (2), 161-199, 2017 | 317 | 2017 |
| Cancer chronotherapeutics: experimental, theoretical, and clinical aspects E Ortiz-Tudela, A Mteyrek, A Ballesta, PF Innominato, F Lévi Circadian clocks, 261-288, 2013 | 101 | 2013 |
| Applying ecological and evolutionary theory to cancer: a long and winding road F Thomas, D Fisher, P Fort, JP Marie, S Daoust, B Roche, C Grunau, ... Evolutionary Applications 6 (1), 1-10, 2013 | 80 | 2013 |
| A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery A Ballesta, S Dulong, C Abbara, B Cohen, A Okyar, J Clairambault, F Levi PLoS computational biology 7 (9), e1002143, 2011 | 79 | 2011 |
| Identification of Circadian Determinants of Cancer Chronotherapy through In Vitro Chronopharmacology and Mathematical Modeling S Dulong, A Ballesta, A Okyar, F Lévi Molecular cancer therapeutics 14 (9), 2154-2164, 2015 | 76 | 2015 |
| Multiscale Design of Cell‐Type–Specific Pharmacokinetic/Pharmacodynamic Models for Personalized Medicine: Application to Temozolomide in Brain Tumors A Ballesta, Q Zhou, X Zhang, H Lv, JM Gallo CPT: pharmacometrics & systems pharmacology 3 (4), 1-11, 2014 | 61 | 2014 |
| Sex‐dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: randomized multicenter EORTC 05011 trial PF Innominato, A Ballesta, Q Huang, C Focan, P Chollet, A Karaboué, ... Cancer medicine 9 (12), 4148-4159, 2020 | 57 | 2020 |
| Circadian rest‐activity rhythm as an objective biomarker of patient‐reported outcomes in patients with advanced cancer PF Innominato, S Komarzynski, OG Palesh, R Dallmann, GA Bjarnason, ... Cancer medicine 7 (9), 4396-4405, 2018 | 54 | 2018 |
| An efficient kinetic model for assemblies of amyloid fibrils and its application to polyglutamine aggregation S Prigent, A Ballesta, F Charles, N Lenuzza, P Gabriel, LM Tine, H Rezaei, ... PloS one 7 (11), e43273, 2012 | 53 | 2012 |
| Systems biology, systems medicine, systems pharmacology: the what and the why A Stéphanou, E Fanchon, PF Innominato, A Ballesta Acta biotheoretica 66, 345-365, 2018 | 47 | 2018 |
| Optimizing circadian drug infusion schedules towards personalized cancer chronotherapy RJW Hill, PF Innominato, F Lévi, A Ballesta PLoS Computational Biology 16 (1), e1007218, 2020 | 40 | 2020 |
| Sex-, feeding-, and circadian time-dependency of P-glycoprotein expression and activity-implications for mechanistic pharmacokinetics modeling A Okyar, SA Kumar, E Filipski, E Piccolo, N Ozturk, H Xandri-Monje, ... Scientific reports 9 (1), 10505, 2019 | 33 | 2019 |
| A mathematical model of the circadian clock and drug pharmacology to optimize irinotecan administration timing in colorectal cancer J Hesse, J Martinelli, O Aboumanify, A Ballesta, A Relógio Computational and Structural Biotechnology Journal 19, 5170-5183, 2021 | 27 | 2021 |
| Bmal1 knockdown leans epithelial–mesenchymal balance toward epithelial properties and decreases the chemoresistance of colon carcinoma cells Y Zhang, A Devocelle, C Desterke, LEB de Souza, É Hadadi, H Acloque, ... International journal of molecular sciences 22 (10), 5247, 2021 | 26 | 2021 |
| Physiologically based mathematical models to optimize therapies against metastatic colorectal cancer: a mini-review A Ballesta, J Clairambault Current pharmaceutical design 20 (1), 37-48, 2014 | 20 | 2014 |
| BMAL1 knockdown triggers different colon carcinoma cell fates by altering the delicate equilibrium between AKT/mTOR and P53/P21 pathways Y Zhang, A Devocelle, L Souza, A Foudi, ST Bento, C Desterke, ... Aging (Albany NY) 12 (9), 8067, 2020 | 19 | 2020 |
| pH as a potential therapeutic target to improve temozolomide antitumor efficacy: A mechanistic modeling study A Stéphanou, A Ballesta Pharmacology Research & Perspectives 7 (1), e00454, 2019 | 18 | 2019 |
| Analysis of a new model of cell population dynamics in acute myeloid leukemia JL Avila, C Bonnet, J Clairambault, H Özbay, SI Niculescu, F Merhi, ... Delay Systems: from Theory to Numerics and Applications, 315-328, 2014 | 17 | 2014 |
| Kinetic analysis of the accumulation of a half-sandwich organo-osmium pro-drug in cancer cells A Ballesta, F Billy, JPC Coverdale, JI Song, C Sanchez-Cano, ... Metallomics 11 (10), 1648-1656, 2019 | 12 | 2019 |
| Theoretical optimization of Irinotecan-based anticancer strategies in the case of drug-induced efflux A Ballesta, J Clairambault, S Dulong, F Levi Applied mathematics letters 24 (7), 1251-1256, 2011 | 12 | 2011 |
